---

---

tags : Fda    symbols : Reta   

save search

---

Reata Pharmaceuticals Announces FDA Filing Acceptance of SKYCLARYS® (Omaveloxlone) NDA Prior Approval Supplement
Published: 2023-06-16 (Crawled : 10:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0 |

Health Technology

| 84.13% | O: 3.5% H: 0.81% C: -3.62%
skyclarys fda approval pharmaceuticals

---

Reata Pharmaceuticals Announces FDA Approval of SKYCLARYS™ (Omavaloxolone), the First and Only Drug Indicated for Patients with Friedreich’s Ataxia
Published: 2023-02-28 (Crawled : 00:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0 |

Health Technology

| 458.7% | O: 0.49% H: 25.61% C: 0.55%
fda pharmaceuticals drug approval friedreich’s ataxia

---

CNS Pharmaceuticals Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Published: 2022-06-23 (Crawled : 13:20) - biospace.com/
RETA | $172.36 0.02% 0.03% 0 |

Health Technology

| 432.63% | O: -0.09% H: 3.99% C: 3.0%
CNSP | $0.1934 -5.2% -5.48% 87K |

Health Technology

| -97.62% | O: 32.07% H: 1.89% C: -24.85%
treatment fda ongoing trial approval berubicin potential

---

Reata Pharmaceuticals Announces FDA Filing Acceptance and Priority Review Designation for the NDA for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia
Published: 2022-05-26 (Crawled : 12:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0 |

Health Technology

| 541.22% | O: 3.53% H: 1.51% C: -0.11%
treatment fda designation review friedreich’s ataxia

---

Reata Pharmaceuticals Initiates Rolling Submission of New Drug Application with U.S. FDA for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia
Published: 2022-01-31 (Crawled : 15:30) - biospace.com/
RETA | $172.36 0.02% 0.03% 0 |

Health Technology

| 592.21% | O: 1.0% H: 13.68% C: 11.81%
new drug treatment fda als application drug one submission friedreich's ataxia friedreich’s ataxia

---

Reata Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Discuss Bardoxolone for the Treatment of Patients With Chronic Kidney Disease Caused by Alport Syndrome
Published: 2021-12-08 (Crawled : 13:30) - biospace.com/
RETA | $172.36 0.02% 0.03% 0 |

Health Technology

| Email alert Add to watchlist
treatment fda disease oda kidney syndros

---

CNS Pharmaceuticals Doses First Group of Patients with Berubicin, an FDA-Designated Fast Track Drug Candidate, in the Potentially Pivotal Study for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2021-09-30 (Crawled : 12:15) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0 |

Health Technology

| 63.64% | O: 0.64% H: 1.89% C: -5.08%
CNSP | $0.1934 -5.2% -5.48% 87K |

Health Technology

| -87.5% | O: -3.75% H: 3.9% C: -3.25%
berubicin treatment fda potential fast track drug designation glioblastoma

---

Reata Pharmaceuticals Plans NDA Submission for Omaveloxolone in First Quarter of 2022 Following Completion of Pre-NDA Meeting with FDA
Published: 2021-09-30 (Crawled : 11:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0 |

Health Technology

| 63.64% | O: 0.64% H: 1.89% C: -5.08%
fda submission

---

WPD Pharmaceuticals’ Licensor Receives FDA Fast Track Designation for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme; WPD Poland Arranges Loans
Published: 2021-07-12 (Crawled : 12:00) - globenewswire.com
RETA | $172.36 0.02% 0.03% 0 |

Health Technology

| 23.6% | O: 1.09% H: 0.94% C: -2.48%
MBRX | $4.65 2.8% 2.72% 11K |

Health Technology

| 36.36% | O: 5.28% H: 0.0% C: -0.56%
CNSP | $0.1934 -5.2% -5.48% 87K |

Health Technology

| -88.95% | O: 7.18% H: 2.06% C: 2.06%
berubicin treatment fda fda fast track fast track fast track designation designation glioblastoma

---

FDA Grants Fast Track Designation to CNS Pharmaceuticals for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme
Published: 2021-06-29 (Crawled : 13:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0 |

Health Technology

| 13.93% | O: 0.5% H: 0.89% C: -3.47%
CNSP | $0.1934 -5.2% -5.48% 87K |

Health Technology

| -90.05% | O: 33.33% H: 0.0% C: -20.52%
berubicin treatment fda fast track fast track designation granted grant designation glioblastoma

---

Reata Announces that The FDA Has Asked The Company to Request a Pre-NDA Meeting for Omaveloxolone for the Treatment of Friedreich’s Ataxia
Published: 2021-05-19 (Crawled : 11:00) - globenewswire.com
RETA | $172.36 0.02% 0.03% 0 |

Health Technology

| 107.89% | O: 13.45% H: 9.49% C: 9.11%
treatment fda friedreich's ataxia friedreich’s ataxia

---

Reata Announces FDA Accepted for Filing the NDA for Bardoxolone for the Treatment of Patients With Chronic Kidney Disease Caused by Alport Syndrome
Published: 2021-04-26 (Crawled : 21:00) - globenewswire.com
RETA | $172.36 0.02% 0.03% 0 |

Health Technology

| 72.24% | O: 3.93% H: 5.77% C: -0.87%
disease treatment fda fda acceptance kidney syndros

---

Gainers vs Losers

67%

33%

Top 10 Gainers

AGBA | News | $1.26 215.0% 68.25% 130M |

Finance

EGOX | $0.0515 43.06% 30.1% 330M |

OLB 4 | $0.33 -14.95% 25.53% 840K |

Technology Services

NVFY | $2.77 31.28% 23.83% 33M |

Consumer Durables

ZCMD | $1.87 28.97% 22.46% 31M |

Commercial Services

RCON | $0.1112 13.01% 21.28% 1.7M |

Distribution Services

INSG | $3.03 25.21% 20.13% 330K |

Electronic Technology

GCTK | $0.8191 22.25% 18.2% 190K |

Manufacturing

WLGS | $0.59 18.0% 17.9% 2.3M |

ASNS | $0.828 21.75% 17.86% 18K |

---

Your saved searches

---